Supportive Care | Specialty

The OncLive Supportive Care condition center page is a comprehensive resource for clinical news and expert insights on supportive care and management of patients with cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, best practices, and ongoing research as it relates to supportive care for patients with cancer.

Imaging and Treatment Advances in Multiple Myeloma

July 10th 2014

Importance of Multidisciplinary Thyroid Cancer Care

July 9th 2014

Treatment Selection in Advanced MTC

July 9th 2014

Utilizing TKIs in Advanced Medullary Thyroid Cancer

July 9th 2014

Diagnosis and Initial Treatment of MTC

July 9th 2014

Managing Sorafenib-Related AEs in Thyroid Cancer

July 9th 2014

Case Study: Treating Papillary Thyroid Cancer

July 9th 2014

Role of the Endocrinologist in RAI-Refractory Thyroid Cancer

July 9th 2014

Patient Selection for Systemic Therapy in DTC

July 9th 2014

Sequencing Therapies in Differentiated Thyroid Cancer

July 9th 2014

Available Treatment Options for RAI-Refractory DTC

July 9th 2014

Determining Treatment for RAI-Refractory Thyroid Cancer

July 9th 2014

Introduction: Radioactive Iodine-Refractory DTC

July 9th 2014

Dr. Keefe on the Role of Supportive Care in Personalized Medicine

July 9th 2014

Dorothy M. K. Keefe, MD, FRACP, past president, MASCC, director, SA Cancer Service, professor of cancer medicine, University of Adelaide, Australia, discusses the role of supportive care in personalized medicine.

Dr. Rapoport on Rolapitant for the Prevention of CINV

July 7th 2014

Bernardo L. Rapoport, MD, chief medical oncologist, The Medical Oncology Center of Rosebank, Johannesburg, South Africa, discusses the utility of rolapitant for preventing chemotherapy-induced nausea and vomiting (CINV).

With ADT in PC, Managing Side Effects Increasingly Important

July 1st 2014

Androgen-deprivation therapy (ADT) is a mainstay of treatment for prostate cancer in a number of settings, so managing its side effects is becoming increasingly important for urologists in collaboration with oncologists and primary-care physicians.

Aprepitant Yields Significant Benefits for the Prevention of CINV in Children

June 28th 2014

Aprepitant is significantly more effective than a comparator placebo-added regimen in preventing CINV in children, with benefits seen across all phases of treatment.

Enobosarm May Prevent Cancer-Induced Muscle Wasting in NSCLC

June 28th 2014

Treatment with enobosarm demonstrated an increase in lean body mass compared with a decline with placebo in patients with non-small cell lung cancer.

Two Phase III Trials Find Rolapitant Effective, Well-Tolerated for Preventing CINV

June 28th 2014

A single oral dose of rolapitant was found to be effective, safe, and long-lasting for the prevention of CINV in patients whose cancer was being treated with either highly or moderately emetogenic chemotherapy.

Single-Dose of Dexamethasone Adequate With Palonosetron for Controlling CINV

June 28th 2014

Palonosetron administered with a single-dose of dexamethasone adequately controlled nausea and vomiting associated with non-anthracycline-based moderately emetogenic chemotherapy when compared with a longer duration of dexamethasone.